SCHEMBL19970083

SCHEMBL19970083

C[C@@]1(C(=O)O)CCCN(c2cccc(SNc3ccc(C(F)(F)F)c(-c4ccccc4Cl)n3)n2)C1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.34
RORC P51449 5/20 0.34
EIF2AK4 Q9P2K8 1/20 0.33
DGAT1 O75907 1/20 0.33
KCNH2 Q12809 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KRAS P01116 1/20 0.32
EPHX2 P34913 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
CHRM4 P08173 1/20 0.31
CNR2 P34972 1/20 0.30
PTPN11 Q06124 1/20 0.30
MAPT P10636 1/20 0.30
KIF18A Q8NI77 1/20 0.30
BRAF P15056 1/20 0.30
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770875 1.00 BTK (0.34) BTKRORCEIF2AK4DGAT1KCNH2
SCHEMBL23770654 0.91 RORC (0.40) BTKRORCMEN1KMT2AKRAS
SCHEMBL19970208 0.90 BTK (0.34) BTKEIF2AK4EPHX2KIF18A
SCHEMBL19970137 0.90 BTK (0.34) BTKEIF2AK4EPHX2KIF18A
SCHEMBL19970081 0.90 BTK (0.33) BTKEIF2AK4EPHX2
SCHEMBL19970020 0.90 RBP4 (0.35) BTKEIF2AK4
SCHEMBL19970129 0.90 RBP4 (0.35) BTKEIF2AK4
SCHEMBL23770792 0.90 EPHX2 (0.34) BTKRORCEIF2AK4EPHX2KIF18A
SCHEMBL19970127 0.90 BTK (0.33) BTKEIF2AK4EPHX2
SCHEMBL19970015 0.90 BTK (0.33) BTKEIF2AK4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 BTK 235/4885RORC 1782/4885EIF2AK4 3294/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 BTK 235/4885RORC 1782/4885EIF2AK4 3294/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 BTK 235/4885RORC 1782/4885EIF2AK4 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.